European Commission Issues Positive Decision for Approval of Seroquel XR
- Details
- Category: AstraZeneca
AstraZeneca announced that the European Commission (EC) has issued a positive decision for the approval of once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy.
Pfizer to Acquire FoldRx Pharmaceuticals
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, have entered into an agreement under which Pfizer will acquire FoldRx. FoldRx's portfolio includes clinical and pre-clinical programs for investigational compounds to treat diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases.
Global market launch of Daxas® (Roflumilast) kicks off in Germany
- Details
- Category: Nycomed
Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas® (Roflumilast) in Oranienburg today, making Germany the first country to market the medicine. Daxas® is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that was developed by Nycomed to treat the progressive, life-threatening lung disease COPD.
Bayer's Rivaroxaban Successfully Meets Primary Efficacy Outcome
- Details
- Category: Bayer
The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant rivaroxaban demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.
Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced its support for inflammatory bowel disease (IBD) fellowships at leading medical institutions across the country.
Genzyme Confirms Receipt of Unsolicited Proposal
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) today confirmed that it has received an unsolicited, non-binding proposal from Sanofi-Aventis to acquire all the outstanding shares of Genzyme for $69 per share in cash. The Genzyme board of directors met last night, unanimously affirmed its previous rejection of Sanofi's proposal, and instructed the company to send Sanofi the following response letter:
Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that it has submitted a non-binding proposal to acquire Genzyme (NASDAQ: GENZ) in an all-cash transaction valued at approximately $18.5 billion.
More Pharma News ...
- Genetic substudy shows fewer major cardiovascular events with ticagrelor (BRILINTA)
- Boehringer Ingelheim inaugurates the Shanghai "Center of Competence"
- Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial Fibrillation
- Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
- Merck Provides New Funding to Fight HIV/AIDS in Botswana
- World Health Organization Grants Prequalification to Prevenar 13
- GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles